The question: How much of the uranium opportunity can each company turn into cash, how long does that take, and what does the current shareholder have to fund along the way?
The video gives us a thesis, not a ticker recommendation
In the interview’s energy discussion, beginning around 10:54, O’Leary argues that electricity supply is a way to participate in the AI buildout. He identifies uranium as an investment theme and emphasizes Canada’s resources. His Finland and Norway comments concern access to inexpensive electricity. The passage does not identify NexGen or Cameco as his stock picks. His disclosed Canadian position in this discussion is the XIU index ETF. Watch the relevant passage.
We should test the supporting claims. Google’s September 9 announcement describes a €13 billion Finnish infrastructure investment, with an initial construction phase in 2027–28. Its energy partnerships include a 22-year agreement with Fortum supporting the Loviisa nuclear plant’s life extension and uprate. That is a concrete connection between computing demand and nuclear generation. It does not establish a supply contract with either company in this comparison. Google’s investment announcement, energy partnerships.
Canada is important, but uranium supply is global. The World Nuclear Association’s 2024 production figures put Kazakhstan at 39%, Canada at 24%, and Namibia at 12%. O’Leary’s emphatic language about Canada should not become a claim that every utility must buy Canadian uranium. Production by country.
One commodity, two stages of the business
CCJ / CCO · Cameco
An operating uranium and fuel-services business, with an investment in Westinghouse. The next question is how production, purchases and contract pricing translate into earnings.
NXE · NexGen
Rook I is under construction. The next question is how funding, engineering and execution translate into a producing mine and eventual shareholder cash flow.
Cameco’s June-quarter release retained 19.5–21.5 million pounds of 2026 uranium-production guidance on its attributable-share basis. It reported C$1.1 billion cash, C$1.0 billion debt, and an undrawn C$1.0 billion revolver. Existing operations reduce the dependence on a single future construction event; operational disruptions, delivery timing and purchase costs still matter. Cameco Q2 results.
NexGen received its federal site-preparation and construction licence in March. Its October presentation says major construction began in June; its September Investor Day agenda describes a 48-month construction schedule. A construction licence is not an operating licence, and a schedule is not a guarantee of commercial production. CNSC decision, NexGen presentation, Investor Day agenda.
The price of uranium is not the price each miner receives
Cameco’s month-end indicator history. Observations are plotted by month; latest prices are September 30.
The September month-end indicators were US$89.63/lb spot and US$96.50/lb long-term. They help describe the market, but neither is a universal realized selling price. Uranium is negotiated privately, and contracts can contain different timing and pricing terms.
Cameco contract sensitivity; NexGen Q2 MD&A, printed page 8. Different measures, assumption dates and currencies; this is not a relative-value ranking.
Under Cameco’s fixed June 30 contract portfolio, moving assumed spot from US$80 to US$100 raises illustrative 2026 realized pricing only from US$66 to US$67. The 2030 figures move from US$76 to US$88. That shows the role of contract terms and time. The table assumes fixed annual spot prices and 2% inflation; it is a sensitivity exercise, not company guidance.
NexGen’s project sensitivity describes a different mechanism. Its Q2 MD&A reproduces the August 2024 interim cost update: at an assumed US$80/lb uranium price, after-tax project NPV at an 8% discount rate is C$4.89 billion; at US$100, it is C$6.79 billion. These are project economics using older cost assumptions, expressed in Q4 2023 dollars. They are not current equity fair values or cash already earned. Debt, corporate costs, timing, financing terms and dilution separate project value from value per share.
NexGen’s quarterly profit needs a second look
NexGen reported C$74.5 million net income in Q2, alongside a C$96.5 million non-cash mark-to-market gain on convertible debentures. Its basic EPS was C$0.11, while diluted EPS was a C$0.02 loss. That is a poor foundation for a headline saying the future uranium producer has become cheap on earnings. The mine has not supplied the operating profits that a conventional producer P/E comparison assumes. Q2 MD&A, printed pages 10–11.
At June 30, NexGen held C$756.2 million cash plus C$214.1 million short-term investments, approximately C$970.3 million combined. That explains the presentation’s rounded C$970 million liquidity figure. Its disclosure also lists US$360 million of convertible-debenture principal. The C$2.2 billion pre-production capital estimate comes from the older interim update; subtracting current cash from that total would not produce a reliable remaining funding gap because spending to date, contingencies and funding structure differ.
Management says it has sufficient cash to fund the company well through construction, while the same MD&A says significant additional financing will be required. The stock analysis needs to examine the eventual funding package and its terms. Do not convert financing options, uranium inventory or an equity investment into cash on hand, or describe the entire project as fully funded without reconciling those disclosures. Q2 MD&A, printed pages 14–15 and 22.
The stock charts have not confirmed the story
Supplied Cameco chart: October 5 close $87.47; October 6 premarket mark $90.20 at 08:20 ET. The mark remains below the displayed 50-day and 200-day averages.
Supplied NexGen chart: October 5 close $9.07; October 6 premarket mark $9.20 at 07:11 ET. Different capture times prevent treating these marks as a synchronized performance comparison.
Daily closes from NXE and CCJ. Equal dates and USD listings; indexed price performance excludes dividends. No volume overlay.
| October 5 close · USD | NXE | CCJ |
|---|---|---|
| Closing price | $9.07 | $87.47 |
| 50-day SMA | $9.96 | $94.61 |
| 200-day SMA | $10.89 | $105.66 |
| Distance below 200-day | 16.7% | 17.2% |
Both closed beneath both averages. That supports a description of unconfirmed price repair, not a claim that either stock must fall. The distance below an average is different from the gain required to regain it. A stronger market case would involve sustained improvement, higher lows and relative strength, rather than treating one green session or one indicator crossing as proof.
What would strengthen each case?
| Evidence to track | Cameco | NexGen |
|---|---|---|
| Business progress | Deliveries, realized pricing, mine reliability and fuel-services economics | Critical-path construction, procurement, permitting for operations and ramp-up |
| Capital discipline | Cash conversion, debt and investment commitments | Remaining capex, committed funding, financing cost and share count |
| Valuation test | Normalize earnings and cash flow; account for Westinghouse and contract timing | Stress project assumptions; bridge project NPV to equity value per diluted share |
| Price confirmation | Track both businesses independently against their own averages, previous highs and relative performance | Track both businesses independently against their own averages, previous highs and relative performance |
Our interpretation: Cameco gives shareholders exposure to a business delivering fuel today. NexGen gives exposure to the possibility of a large new source of supply, with construction and financing between the deposit and shareholder cash flow. A bullish uranium outlook can support both businesses while leaving either stock too expensive for its risks. The difference to price is delivery, timing and how much of the eventual cash flow belongs to today’s shareholder.
Educational commentary. Financial and project data retain their original reporting and assumption dates. Video attribution uses the auto-generated transcript; neither company is presented as O’Leary’s stock pick.